New infections have plateaued for the past 10 years after a steep dip from the peak rate of 3.3 million in 1997, said the authors of a comprehensive analysis in The Lancet HIV journal.
It was published to coincide with the International AIDS conference underway in Durban, South Africa to assess progress in stemming an outbreak that has killed more than 30 million people since the 1980s.
The report paints "a worrying picture of slow progress in reducing new HIV infections," according to lead author Haidong Wang from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, Seattle.
"Therefore, a massive scale-up of efforts from governments and international agencies will be required to meet the estimated USD 36 billion (33 billion euros) needed every year to realise the goal of ending AIDS by 2030," IHME director Christopher Murray said in a statement.
Over the past 15 years, countries have contributed $110 billion in "development assistance" for HIV/AIDS programmes.
Today, there are some 38.8 million people living with the AIDS-causing virus, a steady increase from 28 million in 2000 thanks to the advent in 1996 of life-prolonging antiretroviral therapy (ART).
There is no AIDS cure or vaccine.
ART cocktails suppress the virus, enabling people to live long lives, though the drugs are expensive and can have side effects.
Use of antiretrovirals, for long the preserve of the rich, grew from 6.4 per cent of infected men in 2005 to 38.6 per cent ten years later, and from 3.3 pe rcent to 42.4 per cent for women over the same period, the study found.
Another factor that has helped cut the death rate was education and medicines to prevent infected women passing the virus onto their unborn children, said the report.
In spite of advances, most countries are still far from achieving the UNAIDS goal of ensuring that by 2020, 90 per cent of infected people will know their status, and 90 percent of those will receive ART.
In 2015, 41 percent of HIV-infected people received ART, said the report.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
